That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.» Read More
CNBC's Meg Tirrell and Leonard Schleifer, Regeneron president & CEO, talk about providing fair drug pricing for patients.
How much would it cost world governments to insulate their economies from global pandemics. Would you believe nearly $344 billion?
The Justice Department kept a secret database of incoming and outgoing U.S. international calls for more than a decade.
Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive $115 million to speed development.
Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.
Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.
Healthcare executives talk about their weekend activities.
Healthcare industry executives name the CEOs they'd be most willing to trade places with.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.
Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.
"Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.
David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.
Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.
Shire said it will acquire NPS Pharmaceuticals in an all-stock transaction for about $5.2 billion, the companies said on Sunday.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.
CNBC biotech and pharma reporter Meg Tirrell looks at what to expect from the biggest and most important health care conference of the year. The 33rd annual J.P. Morgan Health Care Conference starts Monday, with 450 companies presenting to almost 9,000 attendees.
Biotech investor Brad Loncar is on a mission to persuade every presenting company at an upcoming biotech conference to also webcast its breakout session.
Biogen Idec's anti-LINGO-1, showed promise in a mid-stage study in reversing the nerve damage associated with acute optic neuritis.
Get the best of CNBC in your inbox